Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Hypoxia-induced PIM kinase and laminin-activated integrin α6 mediate resistance to PI3K inhibitors in bone-metastatic CRPC.

Toth RK, Tran JD, Muldong MT, Nollet EA, Schulz VV, Jensen CC, Hazlehurst LA, Corey E, Durden D, Jamieson C, Miranti CK, Warfel NA.

Am J Clin Exp Urol. 2019 Aug 15;7(4):297-312. eCollection 2019.

2.

Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell-Cell Biophysical Properties in Prostate Cancer.

Rubenstein CS, Gard JMC, Wang M, McGrath JE, Ingabire N, Hinton JP, Marr KD, Simpson SJ, Nagle RB, Miranti CK, Warfel NA, Garcia JGN, Arif-Tiwari H, Cress AE.

Cancer Res. 2019 Sep 15;79(18):4703-4714. doi: 10.1158/0008-5472.CAN-19-0868. Epub 2019 Jul 23.

PMID:
31337652
3.

Targeting PIM kinases to oppose hypoxia-mediated therapeutic resistance.

Chauhan SS, Warfel NA.

Oncoscience. 2018 Aug 22;5(9-10):254-255. doi: 10.18632/oncoscience.458. eCollection 2018 Sep. No abstract available.

4.

Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase.

Song JH, Singh N, Luevano LA, Padi SKR, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, Kraft AS.

Mol Cancer Ther. 2018 Dec;17(12):2710-2721. doi: 10.1158/1535-7163.MCT-18-0374. Epub 2018 Sep 6.

PMID:
30190422
5.

Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents.

Casillas AL, Toth RK, Sainz AG, Singh N, Desai AA, Kraft AS, Warfel NA.

Clin Cancer Res. 2018 Jan 1;24(1):169-180. doi: 10.1158/1078-0432.CCR-17-1318. Epub 2017 Oct 30.

6.

Targeting CDK4/6 to oppose hypoxia-mediated therapeutic resistance.

Warfel NA.

Cell Cycle. 2017 Jul 3;16(13):1241-1242. doi: 10.1080/15384101.2017.1337975. Epub 2017 Jun 8. No abstract available.

7.

Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia.

Toth RK, Warfel NA.

Antioxidants (Basel). 2017 Apr 6;6(2). pii: E27. doi: 10.3390/antiox6020027. Review.

8.

PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species.

Warfel NA, Sainz AG, Song JH, Kraft AS.

Mol Cancer Ther. 2016 Jul;15(7):1637-47. doi: 10.1158/1535-7163.MCT-15-1018. Epub 2016 May 16.

9.

Insulin receptor substrate 1 is a substrate of the Pim protein kinases.

Song JH, Padi SK, Luevano LA, Minden MD, DeAngelo DJ, Hardiman G, Ball LE, Warfel NA, Kraft AS.

Oncotarget. 2016 Apr 12;7(15):20152-65. doi: 10.18632/oncotarget.7918.

10.

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS.

Cancer Res. 2015 Sep 15;75(18):3842-52. doi: 10.1158/0008-5472.CAN-13-1079. Epub 2015 Aug 20.

11.

PIM kinase (and Akt) biology and signaling in tumors.

Warfel NA, Kraft AS.

Pharmacol Ther. 2015 Jul;151:41-9. doi: 10.1016/j.pharmthera.2015.03.001. Epub 2015 Mar 5. Review.

12.

HIF-1 signaling in drug resistance to chemotherapy.

Warfel NA, El-Deiry WS.

Curr Med Chem. 2014;21(26):3021-8. Review.

PMID:
24735366
13.

CDK1 stabilizes HIF-1α via direct phosphorylation of Ser668 to promote tumor growth.

Warfel NA, Dolloff NG, Dicker DT, Malysz J, El-Deiry WS.

Cell Cycle. 2013 Dec 1;12(23):3689-701. doi: 10.4161/cc.26930. Epub 2013 Oct 25.

14.

p21WAF1 and tumourigenesis: 20 years after.

Warfel NA, El-Deiry WS.

Curr Opin Oncol. 2013 Jan;25(1):52-8. doi: 10.1097/CCO.0b013e32835b639e. Review.

PMID:
23159848
15.

CTGF-mediated autophagy-senescence transition in tumor stroma promotes anabolic tumor growth and metastasis.

Prabhu VV, Warfel NA, El-Deiry WS.

Cell Cycle. 2012 Jul 15;11(14):2592-3. doi: 10.4161/cc.21240. Epub 2012 Jul 15. No abstract available.

16.

Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling.

Warfel NA, Newton AC.

J Biol Chem. 2012 Feb 3;287(6):3610-6. doi: 10.1074/jbc.R111.318675. Epub 2011 Dec 5.

17.
18.
19.

Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.

Clin Cancer Res. 2007 Sep 1;13(17):5183-94.

20.

Supplemental Content

Loading ...
Support Center